Premier Fund Managers Ltd Sells 24,484 Shares of Stryker Co. (NYSE:SYK)

Premier Fund Managers Ltd lessened its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 53.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,706 shares of the medical technology company's stock after selling 24,484 shares during the quarter. Premier Fund Managers Ltd's holdings in Stryker were worth $7,864,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Chicago Capital LLC lifted its holdings in shares of Stryker by 3.1% during the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock valued at $70,228,000 after purchasing an additional 5,841 shares in the last quarter. Zhang Financial LLC raised its holdings in Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after buying an additional 40,784 shares during the period. Appleton Partners Inc. MA lifted its stake in Stryker by 5.0% in the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after buying an additional 1,400 shares in the last quarter. Metis Global Partners LLC boosted its holdings in shares of Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock valued at $6,064,000 after buying an additional 1,561 shares during the period. Finally, US Bancorp DE increased its position in shares of Stryker by 0.5% during the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock worth $65,829,000 after acquiring an additional 976 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Remove Ads

Stryker Stock Performance

SYK traded down $0.44 during trading hours on Tuesday, hitting $371.82. The stock had a trading volume of 307,217 shares, compared to its average volume of 1,443,238. The stock has a market cap of $141.92 billion, a PE ratio of 47.91, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company's fifty day simple moving average is $383.86 and its 200 day simple moving average is $374.41.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm posted $3.46 EPS. Equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on SYK shares. JPMorgan Chase & Co. lifted their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Citigroup reaffirmed a "buy" rating and set a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. Stifel Nicolaus lifted their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Barclays increased their target price on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Finally, JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $421.90.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.